Back to Details

regulatory-affairs-head

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Head of Regulatory Affairs

法规事务主管

Regulatory strategy development, submission management, and global market access for medical device organizations.
为医疗设备机构提供监管策略制定、申报管理和全球市场准入服务。

Table of Contents

目录

Regulatory Strategy Workflow

监管策略工作流程

Develop regulatory strategy aligned with business objectives and product characteristics.
制定符合业务目标和产品特性的监管策略。

Workflow: New Product Regulatory Strategy

工作流程：新产品监管策略

  1. Gather product information:
    • Intended use and indications
    • Device classification (risk level)
    • Technology platform
    • Target markets and timeline
  2. Identify applicable regulations per target market:
    • FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo
    • EU: MDR 2017/745, Notified Body requirements
    • Other markets: Health Canada, PMDA, NMPA, TGA
  3. Determine optimal regulatory pathway:
    • Compare submission types (510(k) vs De Novo vs PMA)
    • Assess predicate device availability
    • Evaluate clinical evidence requirements
  4. Develop regulatory timeline with milestones
  5. Estimate resource requirements and budget
  6. Identify regulatory risks and mitigation strategies
  7. Obtain stakeholder alignment and approval
  8. Validation: Strategy document approved; timeline accepted; resources allocated
  1. 收集产品信息：
    • 预期用途和适应症
    • 设备分类（风险等级）
    • 技术平台
    • 目标市场和时间线
  2. 确定目标市场适用的法规：
    • FDA（美国）：21 CFR Part 820、510(k)/PMA/De Novo
    • 欧盟：MDR 2017/745、公告机构要求
    • 其他市场：加拿大卫生部、PMDA、NMPA、TGA
  3. 确定最优监管路径：
    • 比较申报类型（510(k) vs De Novo vs PMA）
    • 评估 predicate 设备的可获得性
    • 评估临床证据要求
  4. 制定含里程碑的监管时间线
  5. 估算资源需求和预算
  6. 识别监管风险及缓解策略
  7. 获取利益相关方的认可和批准
  8. 验证标准：策略文档获批；时间线被接受；资源已分配

Regulatory Pathway Selection Matrix

监管路径选择矩阵

Factor510(k)De NovoPMA
Predicate AvailableYesNoN/A
Risk LevelLow-ModerateLow-ModerateHigh
Clinical DataUsually not requiredMay be requiredRequired
Review Time90 days (MDUFA)150 days180 days
User Fee~$22K (2024)~$135K~$440K
Best ForMe-too devicesNovel low-riskHigh-risk, novel
因素510(k)De NovoPMA
Predicate 设备是否可用是否不适用
风险等级低-中低-中高
临床数据通常不需要可能需要必须提供
审核时间90天（MDUFA）150天180天
用户费用~2.2万美元（2024年）~13.5万美元~44万美元
适用场景同类设备新型低风险设备高风险、新型设备

Regulatory Strategy Document Template

监管策略文档模板

REGULATORY STRATEGY

Product: [Name]
Version: [X.X]
Date: [Date]

1. PRODUCT OVERVIEW
   - Intended use: [Statement]
   - Device classification: [Class I/II/III]
   - Technology: [Description]

2. TARGET MARKETS
   | Market | Priority | Timeline |
   |--------|----------|----------|
   | USA    | 1        | Q1 20XX  |
   | EU     | 2        | Q2 20XX  |

3. REGULATORY PATHWAY
   - FDA: [510(k) / De Novo / PMA]
   - EU: [Class] via [Conformity route]
   - Rationale: [Justification]

4. CLINICAL EVIDENCE STRATEGY
   - Requirements: [Summary]
   - Approach: [Literature / Study / Both]

5. TIMELINE AND MILESTONES
   [Gantt or milestone table]

6. RISKS AND MITIGATION
   | Risk | Probability | Impact | Mitigation |
   |------|-------------|--------|------------|

7. RESOURCE REQUIREMENTS
   - Budget: $[Amount]
   - Personnel: [FTEs]
   - External support: [Consultants, CRO]
REGULATORY STRATEGY

Product: [Name]
Version: [X.X]
Date: [Date]

1. PRODUCT OVERVIEW
   - Intended use: [Statement]
   - Device classification: [Class I/II/III]
   - Technology: [Description]

2. TARGET MARKETS
   | Market | Priority | Timeline |
   |--------|----------|----------|
   | USA    | 1        | Q1 20XX  |
   | EU     | 2        | Q2 20XX  |

3. REGULATORY PATHWAY
   - FDA: [510(k) / De Novo / PMA]
   - EU: [Class] via [Conformity route]
   - Rationale: [Justification]

4. CLINICAL EVIDENCE STRATEGY
   - Requirements: [Summary]
   - Approach: [Literature / Study / Both]

5. TIMELINE AND MILESTONES
   [Gantt or milestone table]

6. RISKS AND MITIGATION
   | Risk | Probability | Impact | Mitigation |
   |------|-------------|--------|------------|

7. RESOURCE REQUIREMENTS
   - Budget: $[Amount]
   - Personnel: [FTEs]
   - External support: [Consultants, CRO]

FDA Submission Workflow

FDA 申报工作流程

Prepare and submit FDA regulatory applications.
准备并提交FDA监管申请。

Workflow: 510(k) Submission

工作流程：510(k) 申报

  1. Confirm 510(k) pathway suitability:
    • Predicate device identified
    • Substantial equivalence supportable
    • No new intended use or technology concerns
  2. Schedule and conduct Pre-Submission (Q-Sub) meeting if needed
  3. Compile submission package:
    • Cover letter and administrative information
    • Device description and intended use
    • Substantial equivalence comparison
    • Performance testing data
    • Biocompatibility (if patient contact)
    • Software documentation (if applicable)
    • Labeling and IFU
  4. Conduct internal review and quality check
  5. Prepare eCopy per FDA format requirements
  6. Submit via FDA ESG portal with user fee payment
  7. Monitor MDUFA clock and respond to AI/RTA requests
  8. Validation: Submission accepted; MDUFA date received; tracking system updated
  1. 确认510(k)路径的适用性：
    • 已确定 predicate 设备
    • 可证明实质性等同
    • 无新的预期用途或技术问题
  2. 如有需要，安排并召开预申报（Q-Sub）会议
  3. 整理申报包：
    • 封面函和行政信息
    • 设备描述和预期用途
    • 实质性等同对比
    • 性能测试数据
    • 生物相容性（若与患者接触）
    • 软件文档（如适用）
    • 标签和使用说明书（IFU）
  4. 进行内部审核和质量检查
  5. 按照FDA格式要求准备电子副本
  6. 通过FDA ESG门户提交并支付用户费用
  7. 监控MDUFA时钟并响应AI/RTA请求
  8. 验证标准：申报被接受；收到MDUFA日期；更新跟踪系统

Workflow: PMA Submission

工作流程：PMA 申报

  1. Confirm PMA pathway:
    • Class III device or no predicate
    • Clinical data strategy defined
  2. Complete IDE clinical study if required:
    • IDE approval
    • Clinical protocol execution
    • Study report completion
  3. Conduct Pre-Submission meeting
  4. Compile PMA submission:
    • Administrative and device information
    • Manufacturing information
    • Nonclinical studies
    • Clinical studies
    • Labeling
  5. Submit original PMA application
  6. Address FDA questions and deficiencies
  7. Prepare for FDA facility inspection
  8. Validation: PMA approved; approval letter received; post-approval requirements documented
  1. 确认PMA路径：
    • III类设备或无 predicate 设备
    • 已定义临床数据策略
  2. 如需完成IDE临床研究：
    • 获取IDE批准
    • 执行临床方案
    • 完成研究报告
  3. 召开预申报会议
  4. 整理PMA申报材料：
    • 行政和设备信息
    • 制造信息
    • 非临床研究
    • 临床研究
    • 标签
  5. 提交原始PMA申请
  6. 回应FDA的问题和缺陷
  7. 准备FDA现场检查
  8. 验证标准：PMA获批；收到批准函；记录获批后要求

FDA Submission Timeline

FDA 申报时间线

Milestone510(k)De NovoPMA
Pre-Sub MeetingDay -90Day -90Day -120
SubmissionDay 0Day 0Day 0
RTA ReviewDay 15Day 15Day 45
Substantive ReviewDays 15-90Days 15-150Days 45-180
DecisionDay 90Day 150Day 180
里程碑510(k)De NovoPMA
预申报会议第-90天第-90天第-120天
申报提交第0天第0天第0天
RTA审核第15天第15天第45天
实质性审核第15-90天第15-150天第45-180天
决策第90天第150天第180天

Common FDA Deficiencies

常见FDA缺陷

CategoryCommon IssuesPrevention
Substantial EquivalenceWeak predicate comparisonStrong SE argument upfront
Performance TestingIncomplete test protocolsFollow recognized standards
BiocompatibilityMissing endpointsISO 10993 risk assessment
SoftwareInadequate documentationIEC 62304 compliance
LabelingInconsistent claimsEarly labeling review
See: references/fda-submission-guide.md
类别常见问题预防措施
实质性等同Predicate 设备对比薄弱提前构建有力的SE论证
性能测试测试方案不完整遵循公认标准
生物相容性缺少终点指标ISO 10993风险评估
软件文档不足符合IEC 62304标准
标签声明不一致提前审核标签
参考：references/fda-submission-guide.md

EU MDR Submission Workflow

EU MDR 申报工作流程

Achieve CE marking under EU MDR 2017/745.
根据EU MDR 2017/745获得CE标志。

Workflow: MDR Technical Documentation

工作流程：MDR技术文档

  1. Confirm device classification per MDR Annex VIII
  2. Select conformity assessment route based on class:
    • Class I: Self-declaration
    • Class IIa/IIb: Notified Body involvement
    • Class III: Full NB assessment
  3. Select and engage Notified Body (for Class IIa+)
  4. Compile Technical Documentation per Annex II:
    • Device description and specifications
    • Design and manufacturing information
    • General Safety and Performance Requirements (GSPR) checklist
    • Benefit-risk analysis and risk management
    • Clinical evaluation per Annex XIV
    • Post-market surveillance plan
  5. Establish and document QMS per ISO 13485
  6. Submit application to Notified Body
  7. Address NB questions and coordinate audit
  8. Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete
  1. 根据MDR附件VIII确认设备分类
  2. 根据类别选择合格评定路径：
    • I类：自我声明
    • IIa/IIb类：公告机构参与
    • III类：公告机构全面评估
  3. 选择并委托公告机构（针对IIa+类）
  4. 根据附件II整理技术文档：
    • 设备描述和规格
    • 设计和制造信息
    • 通用安全和性能要求（GSPR）检查表
    • 获益-风险分析和风险管理
    • 附件XIV规定的临床评价
    • 上市后监督计划
  5. 建立并记录符合ISO 13485的质量管理体系（QMS）
  6. 向公告机构提交申请
  7. 回应公告机构的问题并协调审核
  8. 验证标准：颁发CE证书；签署符合性声明；完成EUDAMED注册

MDR Classification Decision Tree

MDR分类决策树

Is the device active?
        │
    Yes─┴─No
     │     │
     ▼     ▼
Is it an   Does it contact
implant?   the body?
  │            │
Yes─┴─No   Yes─┴─No
 │    │     │     │
 ▼    ▼     ▼     ▼
III  IIb  Check   Class I
         contact  (measuring/
         type     sterile if
         and      applicable)
         duration
Is the device active?
        │
    Yes─┴─No
     │     │
     ▼     ▼
Is it an   Does it contact
implant?   the body?
  │            │
Yes─┴─No   Yes─┴─No
 │    │     │     │
 ▼    ▼     ▼     ▼
III  IIb  Check   Class I
         contact  (measuring/
         type     sterile if
         and      applicable)
         duration

Clinical Evidence Requirements by Class

按类别划分的临床证据要求

ClassClinical RequirementDocumentation
IClinical evaluation (CE)CE report
IIaCE with literature focusCE report + PMCF plan
IIbCE with clinical dataCE report + PMCF + clinical study (some)
IIICE with clinical investigationCE report + PMCF + clinical investigation
类别临床要求文档
I临床评价（CE）CE报告
IIa侧重文献的临床评价CE报告 + PMCF计划
IIb含临床数据的临床评价CE报告 + PMCF + 部分临床研究
III含临床研究的临床评价CE报告 + PMCF + 临床研究

Notified Body Selection Criteria

公告机构选择标准

CriterionConsideration
ScopeDevice category expertise
CapacityAvailability and review timeline
ExperienceTrack record in your technology
GeographyProximity for audits
CostFee structure transparency
CommunicationResponsiveness and clarity
See: references/eu-mdr-submission-guide.md
标准考量因素
范围设备类别专业能力
产能可及性和审核时间线
经验相关技术的过往记录
地域审核便利性
成本费用结构透明度
沟通响应速度和清晰度
参考：references/eu-mdr-submission-guide.md

Global Market Access Workflow

全球市场准入工作流程

Coordinate regulatory approvals across international markets.
协调跨国际市场的监管批准。

Workflow: Multi-Market Submission Strategy

工作流程：多市场申报策略

  1. Define target markets based on business priorities
  2. Sequence markets for efficient evidence leverage:
    • Phase 1: FDA + EU (reference markets)
    • Phase 2: Recognition markets (Canada, Australia)
    • Phase 3: Major markets (Japan, China)
    • Phase 4: Emerging markets
  3. Identify local requirements per market:
    • Clinical data acceptability
    • Local agent/representative needs
    • Language and labeling requirements
  4. Develop master technical file with localization plan
  5. Establish in-country regulatory support
  6. Execute parallel or sequential submissions
  7. Track approvals and coordinate launches
  8. Validation: All target market approvals obtained; registration database updated
  1. 根据业务优先级定义目标市场
  2. 规划市场顺序以高效利用证据：
    • 第一阶段：FDA + 欧盟（参考市场）
    • 第二阶段：互认市场（加拿大、澳大利亚）
    • 第三阶段：主要市场（日本、中国）
    • 第四阶段：新兴市场
  3. 确定各市场的本地要求：
    • 临床数据可接受性
    • 本地代理/代表需求
    • 语言和标签要求
  4. 制定带本地化计划的主技术文件
  5. 建立本地监管支持
  6. 执行并行或顺序申报
  7. 跟踪批准情况并协调上市
  8. 验证标准：获得所有目标市场的批准；更新注册数据库

Market Priority Matrix

市场优先级矩阵

MarketSizeComplexityRecognitionPriority
USALargeHighN/A1
EULargeHighN/A1-2
CanadaMediumMediumMDSAP2
AustraliaMediumLowEU accepted2
JapanLargeHighLocal clinical3
ChinaLargeVery HighLocal testing3
BrazilMediumHighGMP inspection3-4
市场规模复杂度互认性优先级
美国大高无1
欧盟大高无1-2
加拿大中中MDSAP2
澳大利亚中低接受欧盟认证2
日本大高本地临床数据3
中国大极高本地测试3
巴西中高GMP检查3-4

Documentation Efficiency Strategy

文档效率策略

Document TypeSingle SourceLocalization Required
Technical file coreYesFormat adaptation
Risk managementYesNone
Clinical dataYesBridging assessment
QMS certificateYes (ISO 13485)Market-specific audit
LabelingMaster labelTranslation, local requirements
IFUMaster contentTranslation, local symbols
See: references/global-regulatory-pathways.md
文档类型单一源是否需要本地化
技术文件核心是格式调整
风险管理是无需
临床数据是桥接评估
QMS证书是（ISO 13485）市场特定审核
标签主标签翻译+本地要求
使用说明书（IFU）主内容翻译+本地符号
参考：references/global-regulatory-pathways.md

Regulatory Intelligence Workflow

监管情报工作流程

Monitor and respond to regulatory changes affecting product portfolio.
监控并响应影响产品组合的监管变化。

Workflow: Regulatory Change Management

工作流程：监管变更管理

  1. Monitor regulatory sources:
    • FDA Federal Register, guidance documents
    • EU Official Journal, MDCG guidance
    • Notified Body communications
    • Industry associations (AdvaMed, MedTech Europe)
  2. Assess relevance to product portfolio
  3. Evaluate impact:
    • Timeline to compliance
    • Resource requirements
    • Product changes needed
  4. Develop compliance action plan
  5. Communicate to affected stakeholders
  6. Implement required changes
  7. Document compliance status
  8. Validation: Compliance action plan approved; changes implemented on schedule
  1. 监控监管来源：
    • FDA联邦公报、指南文件
    • 欧盟官方公报、MDCG指南
    • 公告机构沟通内容
    • 行业协会（AdvaMed、MedTech Europe）
  2. 评估与产品组合的相关性
  3. 评估影响：
    • 合规时间线
    • 资源需求
    • 所需的产品变更
  4. 制定合规行动计划
  5. 向受影响的利益相关方沟通
  6. 实施所需变更
  7. 记录合规状态
  8. 验证标准：合规行动计划获批；按计划实施变更

Regulatory Monitoring Sources

监管监控来源

SourceTypeFrequency
FDA Federal RegisterRegulations, guidanceDaily
FDA Device Database510(k), PMA, recallsWeekly
EU Official JournalMDR/IVDR updatesWeekly
MDCG GuidanceEU implementationAs published
ISO/IECStandards updatesQuarterly
Notified BodyAudit findings, trendsPer interaction
来源类型频率
FDA联邦公报法规、指南每日
FDA设备数据库510(k)、PMA、召回每周
欧盟官方公报MDR/IVDR更新每周
MDCG指南欧盟实施细则发布时
ISO/IEC标准更新每季度
公告机构审核结果、趋势每次互动时

Impact Assessment Template

影响评估模板

REGULATORY CHANGE IMPACT ASSESSMENT

Change: [Description]
Source: [Regulation/Guidance]
Effective Date: [Date]
Assessment Date: [Date]
Assessed By: [Name]

AFFECTED PRODUCTS
| Product | Impact | Action Required | Timeline |
|---------|--------|-----------------|----------|
| [Name]  | [H/M/L]| [Description]   | [Date]   |

COMPLIANCE ACTIONS
1. [Action 1] - Owner: [Name] - Due: [Date]
2. [Action 2] - Owner: [Name] - Due: [Date]

RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [Hours/FTEs]

APPROVAL
Regulatory: _________________ Date: _______
Management: _________________ Date: _______
REGULATORY CHANGE IMPACT ASSESSMENT

Change: [Description]
Source: [Regulation/Guidance]
Effective Date: [Date]
Assessment Date: [Date]
Assessed By: [Name]

AFFECTED PRODUCTS
| Product | Impact | Action Required | Timeline |
|---------|--------|-----------------|----------|
| [Name]  | [H/M/L]| [Description]   | [Date]   |

COMPLIANCE ACTIONS
1. [Action 1] - Owner: [Name] - Due: [Date]
2. [Action 2] - Owner: [Name] - Due: [Date]

RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [Hours/FTEs]

APPROVAL
Regulatory: _________________ Date: _______
Management: _________________ Date: _______

Decision Frameworks

决策框架

Pathway Selection Decision Tree

路径选择决策树

Is predicate device available?
            │
        Yes─┴─No
         │     │
         ▼     ▼
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       │
         │        Yes─┴─No
     Yes─┴─No      │     │
      │     │      ▼     ▼
      ▼     ▼   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA
Is predicate device available?
            │
        Yes─┴─No
         │     │
         ▼     ▼
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       │
         │        Yes─┴─No
     Yes─┴─No      │     │
      │     │      ▼     ▼
      ▼     ▼   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA

Pre-Submission Meeting Decision

预申报会议决策

FactorSchedule Pre-SubSkip Pre-Sub
Novel Technology✓
New Intended Use✓
Complex Testing✓
Uncertain Predicate✓
Clinical Data Needed✓
Well-established✓
Clear Predicate✓
Standard Testing✓
因素安排预申报跳过预申报
新技术✓
新预期用途✓
复杂测试✓
Predicate 设备不确定✓
需要临床数据✓
成熟领域✓
Predicate 设备明确✓
标准测试✓

Regulatory Escalation Criteria

监管升级标准

SituationEscalation LevelAction
Submission rejectionVP RegulatoryRoot cause analysis, strategy revision
Major deficiencyDirectorCross-functional response team
Timeline at riskManagementResource reallocation review
Regulatory changeVP RegulatoryPortfolio impact assessment
Safety signalExecutiveImmediate containment and reporting
情况升级级别行动
申报被拒法规副总裁根本原因分析、策略修订
重大缺陷总监跨职能响应团队
时间线风险管理层资源重新分配审核
监管变更法规副总裁产品组合影响评估
安全信号高管层立即控制和报告

Tools and References

工具与参考资料

Scripts

脚本

ToolPurposeUsage
regulatory_tracker.pyTrack submission status and timelines
python regulatory_tracker.py
Regulatory Tracker Features:
  • Track multiple submissions across markets
  • Monitor status and target dates
  • Identify overdue submissions
  • Generate status reports
工具用途使用方式
regulatory_tracker.py跟踪申报状态和时间线
python regulatory_tracker.py
监管跟踪器功能：
  • 跟踪跨市场的多个申报
  • 监控状态和目标日期
  • 识别逾期申报
  • 生成状态报告

References

参考资料

DocumentContent
fda-submission-guide.mdFDA pathways, requirements, review process
eu-mdr-submission-guide.mdMDR classification, technical documentation, clinical evidence
global-regulatory-pathways.mdCanada, Japan, China, Australia, Brazil requirements
iso-regulatory-requirements.mdISO 13485, 14971, 10993, IEC 62304, 62366 requirements
文档内容
fda-submission-guide.mdFDA路径、要求、审核流程
eu-mdr-submission-guide.mdMDR分类、技术文档、临床证据
global-regulatory-pathways.md加拿大、日本、中国、澳大利亚、巴西的要求
iso-regulatory-requirements.mdISO 13485、14971、10993、IEC 62304、62366要求

Key Performance Indicators

关键绩效指标（KPI）

KPITargetCalculation
First-time approval rate>85%(Approved without major deficiency / Total submitted) × 100
On-time submission>90%(Submitted by target date / Total submissions) × 100
Review cycle compliance>95%(Responses within deadline / Total requests) × 100
Regulatory hold time<20%(Days on hold / Total review days) × 100
KPI目标计算方式
首次批准率>85%（无重大缺陷获批数 / 总申报数）×100
按时申报率>90%（按目标日期提交数 / 总申报数）×100
审核周期合规率>95%（截止日期内响应数 / 总请求数）×100
监管停滞时间占比<20%（停滞天数 / 总审核天数）×100

Related Skills

相关技能

SkillIntegration Point
mdr-745-specialistDetailed EU MDR technical requirements
fda-consultant-specialistFDA submission deep expertise
quality-manager-qms-iso13485QMS for regulatory compliance
risk-management-specialistISO 14971 risk management
技能集成点
mdr-745-specialist详细的EU MDR技术要求
fda-consultant-specialistFDA申报深度专业知识
quality-manager-qms-iso13485监管合规用质量管理体系（QMS）
risk-management-specialistISO 14971风险管理